AstraZeneca (AZN) Reports Q1 Core EPS of $0.99

AstraZeneca (NYSE: AZN) reported Q1 EPS of $0.99. Revenue for the quarter came in at $5.4 billion versus the consensus estimate of $5.22 billion.

For earnings history and earnings-related data on AstraZeneca (AZN) click here.

You May Also Be Interested In

• AstraZeneca's camizestrant fails primary endpoint in breast cancer trial
• Enhertu shows 14.3-month PFS in first-line lung cancer trial
• TAGRISSO® (osimertinib) demonstrated unprecedented eight-year landmark survival in early-stage EGFR-mutated lung cancer in ADAURA Phase III trial